Non-Fucosylated Anti-Human Clathrin Heavy Chain (Pa65-2) Therapeutic Antibody, an ADCC-Enhanced Biobetter (CAT#: BioBet-728ZP) Datasheet

Target
Clathrin Heavy Chain
Isotype
Mouse IgG
Description
ADCC-Enhanced anti-Clathrin Heavy Chain (Pa65-2) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform. By reducing the fucosylation of the Fc region, the ADCC-enhanced antibody shows an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Cancer
Classification
Therapeutic antibody; biobetter
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CLTC
Full Name
clathrin, heavy chain (Hc)
Background
Clathrin is a major protein component of the cytoplasmic face of intracellular organelles, called coated vesicles and coated pits. These specialized organelles are involved in the intracellular trafficking of receptors and endocytosis of a variety of macromolecules. The basic subunit of the clathrin coat is composed of three heavy chains and three light chains.
Alternative Names
CLTC; clathrin, heavy chain (Hc); Hc; CHC; CHC17; CLH-17; CLTCL2; clathrin heavy chain 1; clathrin, heavy polypeptide (Hc); clathrin, heavy polypeptide-like 2; clathrin heavy chain on chromosome 17
Gene ID
UniProt ID
Cellular Localization
Cytoskeleton
HGNC
OMIM
Involvement in Disease
Diseases associated with CLTC include Mental Retardation, Autosomal Dominant 56 and Renal Cell Carcinoma, Xp11-Associated.
Related Pathways
Its related pathways are Regulation of activated PAK-2p34 by proteasome mediated degradation and Lipoprotein metabolism.
Function
Clathrin is the main protein that covers the polyhedral shell of pits and vesicles. Two different adaptor protein complexes connect the clathrin lattice to the cell membrane or trans-Golgi network. As a component of the TACC3/ch-TOG/clathrin complex, it is believed to help stabilize the centromeric fibers of the mitotic spindle through the action of the microtubule bridge. The TACC3/ch-TOG/clathrin complex is necessary to maintain the tension of the filaments. Participate in early autophagosome formation.
Field of research
Controls and Markers antibody; Signaling Transduction antibody; Endosome Marker antibody
Post-translational modifications
1.Ubiquitination at Lys163, Lys367, Lys389, Lys619, Lys798, Lys856, Lys881, Lys941, Lys1074, Lys1179, Lys1215, Lys1443, and Lys1501 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Mouse IgG
Antibody Clone
Pa65-2
Host
Mouse
Species Reactivity
Human
Description
This is a monoclonal antibody which specifically binds to human clathrin heavy chain (CHC), it can inhibit tumor cell growth and/or angiogenesis, and detect cancer in a subject.
Indication
Cancer

Cancer

All services and products are only for lab research, not for individuals.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

USA-position